Metabolic Dysfunction-Associated Steatohepatitis and Cardiovascular Disease Prevention: Is Resmetirom Useful?

References

1. Younossi Z.M. Golabi P. Paik J.M. Henry A. Van Dongen C. Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology 2023 77 4 1335 1347 10.1097/HEP.0000000000000004 36626630
   [Google Scholar]
2. Muzurović E. Polyzos S.A. Mikhailidis D.P. Non-alcoholic fatty liver disease in children. Curr. Vasc. Pharmacol. 2023 21 1 4 25 10.2174/1570161121666221118155136 36411561
   [Google Scholar]
3. Méndez-Sánchez N. Bugianesi E. Gish R.G. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol. Hepatol. 2022 7 5 388 390 10.1016/S2468‑1253(22)00062‑0 35248211
   [Google Scholar]
4. Rinella M.E. Lazarus J.V. Ratziu V. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023 78 6 1966 1986 10.1097/HEP.0000000000000520 37363821
   [Google Scholar]
5. Kokkorakis M. Muzurović E. Volčanšek Š. Steatotic liver disease: Pathophysiology and emerging pharmacotherapies. Pharmacol. Rev. 2024 76 3 454 499 10.1124/pharmrev.123.001087 38697855
   [Google Scholar]
6. Muzurović E. Peng C.C.H. Belanger M.J. Sanoudou D. Mikhailidis D.P. Mantzoros C.S. Nonalcoholic fatty liver disease and cardiovascular disease: A review of shared cardiometabolic risk factors. Hypertension 2022 79 7 1319 1326 10.1161/HYPERTENSIONAHA.122.17982 35465684
   [Google Scholar]
7. Muzurović E. Mikhailidis D.P. Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 2021 119 154770 10.1016/j.metabol.2021.154770 33864798
   [Google Scholar]
8. Muzurović E. Maćešić M. Kavarić S. Liver fibrosis and atherosclerosis, a consequence of metabolic dysfunction—Do they share a similar pathophysiological background? Angiology 2024 10.1177/00033197241234076 38358750
   [Google Scholar]
9. Rinella M.E. Neuschwander-Tetri B.A. Siddiqui M.S. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023 77 5 1797 1835 10.1097/HEP.0000000000000323 36727674
   [Google Scholar]
10. FDA approves first treatment for patients with liver scarring due to fatty liver disease. 2024 Available from: https://www.prnewswire.com/news-releases/fda-approves-first-treatment-for-patients-with-liver-scarring-due-to-fatty-liver-disease-302089838.html
11. Harrison S.A. Bashir M.R. Guy C.D. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2019 394 10213 2012 2024 10.1016/S0140‑6736(19)32517‑6 31727409
    [Google Scholar]
12. Harrison S.A. Taub R. Neff G.W. Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial. Nat. Med. 2023 29 11 2919 2928 10.1038/s41591‑023‑02603‑1 37845512
    [Google Scholar]
13. Harrison S.A. Bedossa P. Guy C.D. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 2024 390 6 497 509 10.1056/NEJMoa2309000 38324483
    [Google Scholar]
14. Saponaro F. Sestito S. Runfola M. Rapposelli S. Chiellini G. Selective Thyroid Hormone Receptor-Beta (TRβ) agonists: New perspectives for the treatment of metabolic and neurodegenerative disorders. Front. Med. (Lausanne) 2020 7 331 10.3389/fmed.2020.00331 32733906
    [Google Scholar]
15. Angulo P. Kleiner D.E. Dam-Larsen S. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015 149 2 389 397.e10 10.1053/j.gastro.2015.04.043 25935633
    [Google Scholar]
16. Katsiki N. Mikhailidis D.P. Perivascular adipose tissue: Pathophysiological links with inflammation, atherosclerosis, and thrombosis. Angiology 2022 73 3 195 196 10.1177/00033197211014676 34030508
    [Google Scholar]
17. Muzurović E.M. Vujošević S. Mikhailidis D.P. Can we decrease epicardial and pericardial fat in patients with diabetes? J. Cardiovasc. Pharmacol. Ther. 2021 26 5 415 436 10.1177/10742484211006997 33844605
    [Google Scholar]